BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 25868746)

  • 1. Discovery of novel spiro 1,3,4-thiadiazolines as potent, orally bioavailable and brain penetrant KSP inhibitors.
    Mansoor UF; Angeles AR; Dai C; Yang L; Vitharana D; Basso AD; Gray K; Tang H; Liu M; Liang L; Allbritton O; Siddiqui MA
    Bioorg Med Chem; 2015 May; 23(10):2424-34. PubMed ID: 25868746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SCH 2047069, a novel oral kinesin spindle protein inhibitor, shows single-agent antitumor activity and enhances the efficacy of chemotherapeutics.
    Basso AD; Liu M; Dai C; Gray K; Nale L; Tevar S; Lee S; Liang L; Ponery A; Yaremko B; Smith E; Tang H; Sheth PR; Siddiqui MA; Hicklin DJ; Kirschmeier P
    Mol Cancer Ther; 2010 Nov; 9(11):2993-3002. PubMed ID: 20978164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of allosteric inhibitors of kinesin spindle protein (KSP) for the treatment of taxane-refractory cancer: MK-0731 and analogs.
    Cox CD; Garbaccio RM
    Anticancer Agents Med Chem; 2010 Nov; 10(9):697-712. PubMed ID: 21235439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel ATP-competitive kinesin spindle protein inhibitors.
    Parrish CA; Adams ND; Auger KR; Burgess JL; Carson JD; Chaudhari AM; Copeland RA; Diamond MA; Donatelli CA; Duffy KJ; Faucette LF; Finer JT; Huffman WF; Hugger ED; Jackson JR; Knight SD; Luo L; Moore ML; Newlander KA; Ridgers LH; Sakowicz R; Shaw AN; Sung CM; Sutton D; Wood KW; Zhang SY; Zimmerman MN; Dhanak D
    J Med Chem; 2007 Oct; 50(20):4939-52. PubMed ID: 17725339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of a kinesin inhibitor.
    Sakowicz R; Finer JT; Beraud C; Crompton A; Lewis E; Fritsch A; Lee Y; Mak J; Moody R; Turincio R; Chabala JC; Gonzales P; Roth S; Weitman S; Wood KW
    Cancer Res; 2004 May; 64(9):3276-80. PubMed ID: 15126370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of tetrahydro-beta-carbolines as inhibitors of the mitotic kinesin KSP.
    Liu F; Yu LQ; Jiang C; Yang L; Wu WT; You QD
    Bioorg Med Chem; 2010 Jun; 18(12):4167-77. PubMed ID: 20537544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of inhibition of human KSP by monastrol: insights from kinetic analysis and the effect of ionic strength on KSP inhibition.
    Luo L; Carson JD; Dhanak D; Jackson JR; Huang PS; Lee Y; Sakowicz R; Copeland RA
    Biochemistry; 2004 Dec; 43(48):15258-66. PubMed ID: 15568818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developments of kinesin spindle protein inhibitors as antitumor agents based on the five-membered heterocycle scaffolds.
    Zhao GD; Wan RZ; Liu ZP
    Curr Med Chem; 2014; 21(23):2691-701. PubMed ID: 24606497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress on kinesin spindle protein inhibitors as anti-cancer agents.
    Zhang Y; Xu W
    Anticancer Agents Med Chem; 2008 Aug; 8(6):698-704. PubMed ID: 18690830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of KSP Inhibitors as Anti-cancer Therapeutics: An Update.
    Chamariya R; Suvarna V
    Anticancer Agents Med Chem; 2022; 22(14):2517-2538. PubMed ID: 35043768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, biological evaluation and molecular docking studies of flavone and isoflavone derivatives as a novel class of KSP (kinesin spindle protein) inhibitors.
    Dong JJ; Li QS; Liu ZP; Wang SF; Zhao MY; Yang YH; Wang XM; Zhu HL
    Eur J Med Chem; 2013; 70():427-33. PubMed ID: 24184776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitors of kinesin Eg5: antiproliferative activity of monastrol analogues against human glioblastoma cells.
    Müller C; Gross D; Sarli V; Gartner M; Giannis A; Bernhardt G; Buschauer A
    Cancer Chemother Pharmacol; 2007 Feb; 59(2):157-64. PubMed ID: 16703323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the kinesin spindle protein: basic principles and clinical implications.
    Sarli V; Giannis A
    Clin Cancer Res; 2008 Dec; 14(23):7583-7. PubMed ID: 19047082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.
    Sampson PB; Liu Y; Patel NK; Feher M; Forrest B; Li SW; Edwards L; Laufer R; Lang Y; Ban F; Awrey DE; Mao G; Plotnikova O; Leung G; Hodgson R; Mason JM; Wei X; Kiarash R; Green E; Qiu W; Chirgadze NY; Mak TW; Pan G; Pauls HW
    J Med Chem; 2015 Jan; 58(1):130-46. PubMed ID: 24867403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potentiation of kinesin spindle protein inhibitor-induced cell death by modulation of mitochondrial and death receptor apoptotic pathways.
    Vijapurkar U; Wang W; Herbst R
    Cancer Res; 2007 Jan; 67(1):237-45. PubMed ID: 17210704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of inhibition of human KSP by ispinesib.
    Lad L; Luo L; Carson JD; Wood KW; Hartman JJ; Copeland RA; Sakowicz R
    Biochemistry; 2008 Mar; 47(11):3576-85. PubMed ID: 18290633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. K858, a novel inhibitor of mitotic kinesin Eg5 and antitumor agent, induces cell death in cancer cells.
    Nakai R; Iida S; Takahashi T; Tsujita T; Okamoto S; Takada C; Akasaka K; Ichikawa S; Ishida H; Kusaka H; Akinaga S; Murakata C; Honda S; Nitta M; Saya H; Yamashita Y
    Cancer Res; 2009 May; 69(9):3901-9. PubMed ID: 19351824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinesin spindle protein (KSP) inhibitors. Part 1: The discovery of 3,5-diaryl-4,5-dihydropyrazoles as potent and selective inhibitors of the mitotic kinesin KSP.
    Cox CD; Breslin MJ; Mariano BJ; Coleman PJ; Buser CA; Walsh ES; Hamilton K; Huber HE; Kohl NE; Torrent M; Yan Y; Kuo LC; Hartman GD
    Bioorg Med Chem Lett; 2005 Apr; 15(8):2041-5. PubMed ID: 15808464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mcl-1 stability determines mitotic cell fate of human multiple myeloma tumor cells treated with the kinesin spindle protein inhibitor ARRY-520.
    Tunquist BJ; Woessner RD; Walker DH
    Mol Cancer Ther; 2010 Jul; 9(7):2046-56. PubMed ID: 20571074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thermodynamics of nucleotide and inhibitor binding to wild-type and ispinesib-resistant forms of human kinesin spindle protein.
    Sheth PR; Basso A; Duca JS; Lesburg CA; Ogas P; Gray K; Nale L; Mannarino AF; Prongay AJ; Le HV
    Biochemistry; 2009 Nov; 48(46):11045-55. PubMed ID: 19824700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.